Global Synergy — The 2026 CGT Summit and Clinical Trials
In 2026, Seoul continues to rank as the city with the highest number of pharma-led clinical trials globally.
This status is reinforced by major international events like the DIA Korea Cell and Gene Therapy Summit (February 2026) and the CGT East Asia Congress (September 2026). These summits highlight South Korea's role as a "bridge" for Western biotech companies looking to access Asian markets. By 2026, the South Korean government has invested over $1.7 billion into the biotech sector, specifically targeting "translational science" to help early-stage domestic startups move their gene therapy candidates through Phase II trials locally before licensing them to global "Big Pharma."
1 View